A knowledgebase of validated abnormal editing events associated with hematopoietic malignancy

This module incorporates 12 hematopoietic malignancies associated with 26 experimentally validated abnormal RNA editing events, which include 17 mRNAs and 2 miRNAs and 7 viruses, and 23 aberrant activities involved with 5 editing enzymes. The informations are curated from 24 publications.



Category

Editing Type:
Gene biotype:
Enzyme:
Disease
name		 Species Gene
name		 Gene
type		 Virus host Enzyme Editing
site(s)		 Editing
type		 Editing
effect		 PMID Position
primary effusion lymphoma human pri-miRNA-K12-4 miRNA Kaposis sarcoma-associated herpesvirus human ADAR1 3 A-to-I They leverage a combination of biochemical and genomic approaches to determine the RNA editing landscape in host- and KSHV transcriptomes during both latent and lytic replication in PEL. Analysis of RNA editomes reveals it is dynamic, with increased editi 36914661 KSHV genome (GQ994935.1) . miR cluster121877121923121925
primary effusion lymphoma human KaposinA mRNA Kaposis sarcoma-associated herpesvirus human ADAR1 1 A-to-I They leverage a combination of biochemical and genomic approaches to determine the RNA editing landscape in host- and KSHV transcriptomes during both latent and lytic replication in PEL. Analysis of RNA editomes reveals it is dynamic, with increased editi 36914661 KSHV genome (GQ994935.1).117809
primary effusion lymphoma human ATR mRNA Kaposis sarcoma-associated herpesvirus human ADAR1 1 A-to-I They leverage a combination of biochemical and genomic approaches to determine the RNA editing landscape in host- and KSHV transcriptomes during both latent and lytic replication in PEL. Analysis of RNA editomes reveals it is dynamic, with increased editi 36914661 KSHV genome (GQ994935.1).ORF50:73502
primary effusion lymphoma human NOP14 mRNA 3 A-to-I They leverage a combination of biochemical and genomic approaches to determine the RNA editing landscape in host- and KSHV transcriptomes during both latent and lytic replication in PEL. Analysis of RNA editomes reveals it is dynamic, with increased editi 36914661 chr4:2938358,2938420,2938437
primary effusion lymphoma human AJUBA mRNA 8 A-to-I They leverage a combination of biochemical and genomic approaches to determine the RNA editing landscape in host- and KSHV transcriptomes during both latent and lytic replication in PEL. Analysis of RNA editomes reveals it is dynamic, with increased editi 36914661 chr14:22972905,22972911,22972912,22972913,22972932,22972941,22972942,22972943
primary effusion lymphoma human MAVS mRNA 4 A-to-I They leverage a combination of biochemical and genomic approaches to determine the RNA editing landscape in host- and KSHV transcriptomes during both latent and lytic replication in PEL. Analysis of RNA editomes reveals it is dynamic, with increased editi 36914661 chr20:3872338,3872340,3872359,3872364
Acute Lymphocytic Leukemia human Pax-5 mRNA >1 A-to-I Upon the profiling of Pax-5 mRNA in leukemic cells, we found that the 3end of the Pax-5 transcript is submitted to alternative polyadenylation (APA) and alternative splicing events 35011638 3UTR
Acute myeloid leukemia human PTPN6 mRNA 1 A- to-I The involvement of post-transcriptional PTPN6 processing in leukemogenesis. The editing of PTPN6 mRNA mainly occurred as an A-->G conversion of A(7866), which represents the putative branch site in IVS3 of PTPN6 mRNA.And it results that aberrant splicing 11001933 Intron A7866
Acute myeloid leukemia human LDLR mRNA APOBEC3A 1 G-to-C Alternative RNA editing of l low density lipoprotein (LDL) receptor (R) gene leads to a new cryptic acceptor splice site 17 bp downstream in exon 8 producing a frameshift mutation and a predicted premature stop codon 1138 bp from the transcriptional start 10487495 intron 7 [1061(-1)]
Blast crisis chronic myeloid leukemia human GSK3 mRNA ADAR1 NA A-to-I Editing induces mis-splicing of GSK3 leading to leukemic stem cell renewal. 16369484 Intron
Blast crisis chronic myeloid leukemia human MDM2 mRNA ADAR1 NA A-to-I Editing of the 3UTR of MDM2 prevents targeting by mi155, thereby inhibiting the transcriptional activation of p53 and contributing to the progression to BC CML. 30612940 3UTR
Chronic Lymphocytic Leukemia has-mir-3157 miRNA ADAR1 1 A-to-G hsa-miR-3157 are edited within the seed region in a subset of CLL samples but not in B cells. These editing events alter miRNA target specificity and likely affect the pathogenesis of the disease. 32728184 NA
Chronic Lymphocytic Leukemia human FLNB mRNA ADAR1 1 A-to-I They determined global RNA editing and recurrent, recoding RNA editing events from matched RNA-sequencing and whole exome sequencing data in CLL samples from 45 untreated patients. RNA editing was verified in a validation cohort of 98 CLL patients and rev 32728184 chr3:58141791
Chronic Lymphocytic Leukemia human BLCAP mRNA ADAR1 1 A-to-I They determined global RNA editing and recurrent, recoding RNA editing events from matched RNA-sequencing and whole exome sequencing data in CLL samples from 45 untreated patients. RNA editing was verified in a validation cohort of 98 CLL patients and rev 32728184 chr20:36147572
Chronic Lymphocytic Leukemia human AZIN1 mRNA ADAR1 1 A-to-I They determined global RNA editing and recurrent, recoding RNA editing events from matched RNA-sequencing and whole exome sequencing data in CLL samples from 45 untreated patients. RNA editing was verified in a validation cohort of 98 CLL patients and rev 32728184 chr8:103841636
Chronic Lymphocytic Leukemia human PI4K2A mRNA ADAR1 1 A-to-I They determined global RNA editing and recurrent, recoding RNA editing events from matched RNA-sequencing and whole exome sequencing data in CLL samples from 45 untreated patients. RNA editing was verified in a validation cohort of 98 CLL patients and rev 32728184 chr10:99424675
Chronic Lymphocytic Leukemia human TOR1B mRNA ADAR1 1 A-to-I They determined global RNA editing and recurrent, recoding RNA editing events from matched RNA-sequencing and whole exome sequencing data in CLL samples from 45 untreated patients. RNA editing was verified in a validation cohort of 98 CLL patients and rev 32728184 chr9:132571671
Chronic Myeloid Leukemia human hsa-let-7a-1 miRNA ADAR1 2 A-to-I ADAR1 regulates let-7 miRNA biogenesis in an A-to-I editing dependent manner, it promotes the self-renewal and survival capability of chronic myeloid leukemia Leukemic stem cells. 27494666,27292180 chr9:94,108,803..94,108,881(pri-let-7d+3,+59)
Infectious mononucleosis and multiple cancers human NA NA Epstein-Barr virus Human APOBEC3B NA 30420783 NA
Leukemia human NA NA Human T-cell leukemia virus type 2 Human ADAR1 NA 22993189 NA
Leukemia human NA NA Human T-lymphotropic virus type 1 Human APOBEC3G; APOBEC3A; APOBEC3B NA 22457529 NA
Leukemia human NA NA Simian T-cell leukemia virus type 3 Simian ADAR1 NA 22993189 NA
lymphoma human NA NA APOBEC3G NA C-to-U APOBEC3G is an endogenous RNA editing enzyme in primary natural killer cells and lymphoma cell lines. This RNA editing is induced by cellular crowding and mitochondrial respiratory inhibition to promote adaptation to hypoxic stress. 30791937 NA
Multiple Myeloma human GLI1 mRNA ADAR1 1 A-to-I ADAR1 enhances Alu dependent editing and transcriptional activity of GLI1, Notably, GLI1 transcript editing rates were significantly higher in relapsed multiple myeloma than age-matched controls 29203771 Exon12
Multiple myeloma human NEIL1 mRNA ADAR1 NA A-to-I Edited NEIL1 has reduced oxidative DNA damage repair capability, rendering myeloma to be more sensitive to single double-stranded break inducing agent or in combination with single-stranded DNA break inducing agent. 16369484,30061158 Exon6 A726
Severe hemorrhagic disease human GP mRNA Ebola virus Human; Monkey; Guinea pig; Mice ADAR1 >1 26703716,26138826,21987773,21411529,8553543,24146620,25370495 EBOV genome (nt 6378 ~ 6383)
Virus infected disease mice NA NA Murine leukemia virus Mice APOBEC3 NA 29593034,23671100 NA